



**Engadine Partners LLP - Annual Best Execution Disclosure 2017**

Calendar Year Disclosure Period: 1 January 2017 to 31 December 2017

Date: 30 April 2018

This report contains a summary of classes of instruments traded only, any class of instruments not included in this report is because the Firm has not executed client orders in that class of instruments.

Class of Instrument Notification if <1 average trade per day	Equities – Shares & Depositary Receipts Tick Size Liquidity Bands 1 and 2					
	No					
Top five execution venues (desc. order)	LEI	% of Volume	% of Orders	% of Passive Orders	% of Agressive Orders	% of Directed Orders
UBS Limited	REYPIEJN7XZHSUI0N355	40.41	39.63	N/A	N/A	N/A
Morgan Stanley & Co International Plc	4PQUHN3JPFQFNF3BB653	35.94	34.55	N/A	N/A	N/A
Bank of America Merrill Lynch	8NAV47TOY26Q87Y0QP81	7.23	9.55	N/A	N/A	N/A
Goldman Sachs International	W22LROWP2IHZNBB6K528	6.39	6.71	N/A	N/A	N/A
Instinet Europe Limited	213800MXAKR2LA1VBM44	3.58	4.07	N/A	N/A	N/A

Class of Instrument Notification if <1 average trade per day	Equities – Shares & Depositary Receipts Tick Size Liquidity Bands 3 and 4					
	No					
Top five execution venues (desc. order)	LEI	% of Volume	% of Orders	% of Passive Orders	% of Agressive Orders	% of Directed Orders
Morgan Stanley & Co International Plc	4PQUHN3JPFQFNF3BB653	26.05	28.18	N/A	N/A	N/A
UBS Limited	REYPIEJN7XZHSUI0N355	23.71	24.90	N/A	N/A	N/A
Liquidnet Europe Limited	213800ZIRB79BE5XQM68	13.38	9.79	N/A	N/A	N/A
Goldman Sachs International	W22LROWP2IHZNBB6K528	12.02	11.75	N/A	N/A	N/A
JP Morgan Securities Plc	K6Q0W1PS1L1O4IQL9C32	10.88	9.79	N/A	N/A	N/A

Class of Instrument Notification if <1 average trade per day	Equities – Shares & Depositary Receipts Tick Size Liquidity Bands 5 and 6					
	No					
Top five execution venues (desc. order)	LEI	% of Volume	% of Orders	% of Passive Orders	% of Agressive Orders	% of Directed Orders
Morgan Stanley & Co International Plc	4PQUHN3JPFQFNF3BB653	23.81	27.54	N/A	N/A	N/A
UBS Limited	REYPIEJN7XZHSUI0N355	19.86	23.73	N/A	N/A	N/A
JP Morgan Securities Plc	K6Q0W1PS1L1O4IQL9C32	13.54	9.99	N/A	N/A	N/A
Goldman Sachs International	W22LROWP2IHZNBB6K528	12.35	12.96	N/A	N/A	N/A
Liquidnet Europe Limited	213800ZIRB79BE5XQM68	9.26	5.67	N/A	N/A	N/A

Class of Instrument Notification if <1 average trade per day	Debt Instruments - Bonds					
	Yes					
Top five execution venues (desc. order)	LEI	% of Volume	% of Orders	% of Passive Orders	% of Agressive Orders	% of Directed Orders
Mediobanca	PSNL19R2RXX5U3QWHI44	100	100	N/A	N/A	N/A

Class of Instrument Notification if <1 average trade per day	Contracts for Difference - Equity					
	No					
Top five execution venues (desc. order)	LEI	% of Volume	% of Orders	% of Passive Orders	% of Agressive Orders	% of Directed Orders
Morgan Stanley & Co International	4PQUHN3JPFQFNF3BB653	29.06	25.68	N/A	N/A	N/A
UBS Limited	REYPIEJN7XZHSUI0N355	23.59	20.69	N/A	N/A	N/A
Goldman Sachs International	W22LROWP2IHZNBB6K528	11.97	12.30	N/A	N/A	N/A
JP Morgan Securities Plc	K6Q0W1PS1L1O4IQL9C32	9.15	12.78	N/A	N/A	N/A
Bank of America Merrill Lynch	8NAV47TOY26Q87Y0QP81	6.38	5.31	N/A	N/A	N/A

Class of Instrument Notification if <1 average trade per day	Currency Derivatives - Swaps, forwards, and other currency derivatives					
	No					
Top five execution venues (desc. order)	LEI	% of Volume	% of Orders	% of Passive Orders	% of Agressive Orders	% of Directed Orders
Goldman Sachs International	W22LROWP2IHZNBB6K528	61.34	67.69	N/A	N/A	N/A
Morgan Stanley & Co International Plc	4PQUHN3JPFQFNF3BB653	38.66	32.31	N/A	N/A	N/A

Class of Instrument Notification if <1 average trade per day	Debt Instruments - Money Market Instruments					
	No					
Top five execution venues (desc. order)	LEI	% of Volume	% of Orders	% of Passive Orders	% of Agressive Orders	% of Directed Orders
Goldman Sachs International	W22LROWP2IHZNBB6K528	71.47	55.28	N/A	N/A	N/A
UBS Limited	REYPIEJN7XZHSUI0N355	25.87	35.75	N/A	N/A	N/A
Morgan Stanley & Co International Plc	4PQUHN3JPFQFNF3BB653	2.67	8.97	N/A	N/A	N/A



Engadine Partners LLP - Annual Best Execution Disclosure 2017

Best Execution Qualitative Information

<p>A summary of the analysis and conclusions the firm draws from its detailed monitoring of the quality of execution obtained on the execution venues where it executed all client orders in the previous year</p>	<p><b>(a) Equities - Shares &amp; Depositary Receipts</b>  As part of Engadine Partners LLP ("Engadine")'s analysis of best execution in relation to equities, the Firm analysed the trades during the relevant period to determine whether any of the trades were executed at a price outside of an internally defined variance of the Volume Weighted Average Price ("VWAP"). Where any trades were found to be outside of the tolerance, Compliance investigated to determine the cause.</p> <p>The monitoring completed supported that best execution was obtained consistently on the approved execution venues throughout the year.</p> <p><b>(b) Debt Instruments</b>  As part of the Firm's analysis of best execution in relation to debt instruments, reviews of externally verifiable reference prices (where available) were undertaken when pricing or checking the price of bids/offers. The monitoring completed supported that best execution was obtained consistently on the approved execution venues throughout the year.</p> <p><b>(e) Currency Derivatives</b>  As part of the Firm's analysis of best execution in relation to currency derivatives, reviews were undertaken of the of the established request for quote ("RFQ") process, which involves obtaining competing quotes from counterparties to assess a spread of all quoted prices to illustrate RFQ competitiveness.</p> <p>The monitoring completed supported that best execution was obtained consistently on the approved execution venues throughout the year.</p> <p><b>(g) Equity Derivatives</b>  As part of Engadine's analysis of best execution in relation to equity derivatives, the Firm analysed a sample of the trades during the relevant period to determine whether they were executed in-line with exchange-traded levels and, where relevant, examined the RFQ process to determine this was carried out in accordance with internally established protocols.</p> <p>The monitoring completed supported that best execution was obtained consistently on the approved execution venues throughout the year.</p> <p><b>(j) Contracts for difference</b>  As part of Engadine's analysis of best execution in relation to contracts for difference, the Firm analysed a sample of trades during the relevant period to determine whether any of the trades were executed at a price outside of an internally defined tolerance to a pre-determined benchmark for the underlying. Where any trades were found to be outside the tolerance, Compliance investigated to determine the cause.</p> <p>The monitoring completed supported that best execution was obtained consistently on the approved execution venues throughout the year.</p>
<p>An explanation of the relative importance the firm gave to the execution factors of price, costs, speed, likelihood of execution or any other consideration including qualitative factors when assessing the quality of execution</p>	<p>Engadine's delivery of best execution is a key element in its commitment to act in the best interests of its clients, as well as being a regulatory requirement. The Firm prioritises ensuring that all sufficient steps are taken to obtain the best possible result for its clients when it executes, places or transmits orders on their behalf. This means taking into account the 'execution factors' such as price, costs, speed, likelihood of execution and settlement, size, nature or any other consideration relevant to the execution of the order.</p> <p>The relative importance of the execution factors is judged on an order-by-order basis in line with the Firm's industry experience and prevailing market conditions. In addition, common key factors for relevant asset classes have been identified as follows:</p> <p><b>(a) Equities - Shares &amp; Depositary Receipts</b>  For small indirect orders over a short period of time, the key factors are generally price, quantity based on market availability, and likelihood of execution. For larger orders executed over a longer period of time, the Firm additionally takes into account confidentiality, minimising the impact on the market, and slippage historically achieved on each venue.</p> <p>Where transactions are executed indirectly, relevant factors are overall costs including broker fee schedules, impact and observed slippage.</p> <p>The impact of implicit costs is taken into account when considering the execution strategy of orders to ensure that they are managed and do not result in an undue impact to total costs.</p> <p><b>(b) Debt Instruments</b>  Due to the nature of debt instruments, the Firm will typically place price, size and the nature of the transaction as of primary importance.</p> <p><b>(e) Currency Derivatives (ii) Swaps, Forwards, and other Currency Derivatives</b>  Where derivatives are executed directly, key factors considered are price, size and overall transaction costs. Prices are compared via an RFQ, taking into account additional transaction costs that may be applicable. When transactions are time-sensitive, response time to RFQ is often a defining factor. On occasion, preference is given to counterparties that are operationally easier to work with where time factors are a consideration.</p> <p>Where orders are executed indirectly, relevant factors are costs and the existing counterparty relationship.</p> <p><b>(g) Equity Derivatives</b>  Due to the nature of the orders the Firm will typically place size, price and cost as of primary importance</p> <p><b>(j) Contracts for difference</b>  As part of Engadine's analysis of best execution in relation to contracts for difference, the Firm analysed a sample of trades during the relevant period to determine whether any of the trades were executed at a price outside of an internally defined tolerance to a pre-determined benchmark for the underlying. Where any trades were found to be outside the tolerance, Compliance investigated to determine the cause.</p> <p>The monitoring completed supported that best execution was obtained consistently on the approved execution venues throughout the year.</p>

<b>A description of any close links, conflicts of interests, and common ownerships with respect to any execution venues used to execute orders</b>	<b>Applies across all classes of financial instruments traded.</b>  The Firm does not have any close links, conflicts of interests or common ownerships with respect to the execution venues it uses to execute orders.
<b>A description of any specific arrangements with any execution venues regarding payments made or received, discounts, rebates or non-monetary benefits received</b>	<b>Applies across all classes of financial instruments traded.</b>  The Firm has determined that it will pay for research from its Research Payment Account ("RPA"). Additionally, Engadine may on occasion receive or provide minor non-monetary benefits from execution venues. They must be received/provided in accordance with the Firm's Inducements policy.  When selecting execution venues for inclusion in the execution policy, the Firm does not take into account the non-monetary benefits it may obtain in connection with the services provided to its clients, but focuses on the potential of the venues to enable the Firm to obtain on a consistent basis the best possible result for the execution of its client orders. However, the Firm does take into account the effect of fees and commission when choosing a venue for the execution of a particular client order.
<b>An explanation of the factors that led to a change in the list of execution venues listed in the firm's execution policy, if such a change occurred</b>	<b>Applies across all classes of financial instruments traded.</b>  During the period under review, Engadine's list of execution venues changed. The Firm regularly reviews the effectiveness of its Best Execution Policy and its execution arrangements to identify and, where appropriate, incorporate any changes to enhance the quality of execution obtained. Following discussions with front office staff and as part of the reviews carried out over the period it was determined that certain changes involving both addition and removal of certain counterparties were required to ensure that the Firm continues to obtain the best possible result for its clients. Factors considered included price, access to the market, counterparty risk and market liquidity.
<b>An explanation of how order execution differs according to client categorisation, where the firm treats categories of clients differently and where it may affect the order execution arrangements</b>	<b>Applies across all classes of financial instruments traded.</b>  While Engadine does take the characteristics of its clients into account when judging the relative importance of the execution factors, the Firm's clients are exclusively professional clients and so are treated with a consistent approach.
<b>An explanation of whether other criteria were given precedence over immediate price and cost when executing retail client orders and how these other criteria were instrumental in delivering the best possible result in terms of the total consideration to the client</b>	<b>Applies across all classes of financial instruments traded.</b>  Not applicable. The Firm does not execute retail client orders.
<b>An explanation of how the Firm has used any data or tools relating to the quality of execution, including any data published under Commission Delegated Regulation (EU) 2017/575</b>	<b>Applies across all classes of financial instruments traded.</b>  Engadine does not currently use data or tools relating to the quality of execution, but will utilise such data and tools as are made available in due course, particularly data published by trading venues under 'RTS 27'. Where the Firm directly executes transactions on behalf of its client with counterparties where the order relates to OTC products, the Firm takes steps to check the fairness of the price on offer by gathering market data used in the estimation of the price of such product and, where possible, by comparing with similar or comparable products
<b>Where applicable, an explanation of how the investment firm has used output of a consolidated tape provider established under Article 65 of Directive 2014/65/EU.</b>	<b>Applies across all classes of financial instruments traded.</b>  This is not currently applicable as the services of a Consolidated Tape Provider were not available during the period to which this disclosure relates.

**DISCLAIMER:** This document is issued by Engadine Partners LLP ("Engadine") which is authorised and regulated by the UK Financial Conduct Authority ("FCA") and registered as an exempt reporting adviser with the Securities and Exchange Commission of the United States of America.

The investment products and services of Engadine are only available to persons who are professional clients and eligible counterparties for the purposes of the FCA's rules, they are not available to retail clients. This document refers to funds managed by Engadine (the "Funds").

This document does not provide or offer financial, investment, tax, legal, regulatory or other advice and recipients of this document ("Recipients") must not rely on it as providing any form of advice. Recipients who may be considering making an investment in the Funds should seek their own independent advice.

This document is not a financial promotion and is not intended for public use or distribution. The information contained in this manager's report is strictly confidential and is intended only for use of the individual to whom Engadine has provided the document. No part of this document may be divulged to any other person, distributed, resold and/or reproduced without the prior written permission of Engadine.

This document is for information purposes only and does not constitute or form part of any invitation, offer to issue or sell, or any solicitation to engage in any investment activity (including to buy or invest in, shares, units or interests in any Fund) or an offering or placement of shares, units or interests in any Fund, nor shall it or the fact of its distribution form the basis of, or be relied on in connection with, any contract thereof. Further information on the Funds, including a discussion of the risks of an investment in a particular Fund, is set out in the relevant Fund's offering memorandum or prospectus. Recipients should refer only to the offering memorandum or prospectus when deciding whether to invest in any Fund.

The returns specified in this document reflect the most current data at the time of issue. These returns may be amended due to re-pricing adjustments or receipt of more accurate data, among other things, and may be reflected in the next report. Opinions expressed are Engadine's present opinions only, reflecting prevailing market conditions and certain assumptions (which may not prove to be valid). The information and opinions contained in this document are non-binding and do not purport to be full or complete. Recipients should appreciate that the value of any investment, and any income from any investment, may go down as well as up and that the capital of an investor in the Funds is at risk and that the investor may not receive back, on redemption or withdrawal of his investment, the amount which he invested. Past performance is not necessarily indicative of future results. Changes in rates of currency exchange may cause the value of an investment to go up or down.

All information contained in this document is obtained from sources Engadine believes to be reliable, but which have not been independently verified. To the greatest extent permitted by law and by the handbook of rules and guidance issued from time to time by the FCA: (i) neither Engadine, nor the Funds, nor any of its or their or their affiliates' directors, partners, officers or employees (together, "Relevant Persons"), make any guarantee, representation or warranty as to the accuracy or completeness of the contents of this document; and (ii) no Relevant Person accepts any responsibility or liability for any loss of profit, indirect or other consequential losses or other economic losses suffered by any person arising from reliance upon any information, statement or opinion contained in this document (whether such losses are caused by the negligence of the Relevant Person or otherwise).

All information in this document is expressed as at its date and is subject to changes at any time without prior notice or other publication of such changes.

The Fund referred to in this document has not been registered, or authorized or approved by any regulatory authority. The Fund has not been and cannot be registered with the Swiss Financial Market Supervisory Authority (FINMA) and the Shares cannot be distributed in Switzerland to non-qualified investors. Any distribution of the Shares in Switzerland will be exclusively made to, and directed at, qualified investors ("Qualified Investors"), as defined in the Swiss Collective Investment Schemes Act dated June 23, 2006 and revised on September 28, 2012, or its implementing ordinance.

This document may be made available in Switzerland solely to Qualified Investors by the representative of the Fund in Switzerland and/or any authorized distributor (or to investors that invest in the Fund on their own initiative in a manner that does not involve any distribution). The representative in Switzerland is Hugo Fulle Services SA registered office is at 6, Cours de Rive, CH-1204 Geneva, Switzerland. The Paying Agent of the Fund in Switzerland is Banque Cantonale de Geneve whose registered office is at 17, quai de l'île, 1204 Geneva, Switzerland. The place of performance and jurisdiction for Shares of the Fund distributed in Switzerland is the registered office of the representative.